10-Q: Myriad Genetics Reports 15% Revenue Growth in Second Quarter, Driven by Strong Performance in Prenatal and Pharmacogenomics Testing

Myriad Genetics saw a 15% year-over-year increase in revenue for the second quarter of 2024, fueled by growth in prenatal and pharmacogenomics testing volumes and average revenue per test.

Summary

• Myriad Genetics reported a 15% increase in revenue for the second quarter of 2024, reaching $211.5 million, compared to $183.5 million in the same period last year.
• The company's testing volumes grew by 9% year-over-year, with prenatal testing volumes increasing by 12% and pharmacogenomics testing volumes increasing by 10%.
• Hereditary cancer testing volumes increased by 3%, while tumor profiling testing volumes decreased by 13%.
• The company experienced a net loss of $36.7 million, or $0.41 per share, for the quarter, compared to a net loss of $116.1 million, or $1.42 per share, in the prior year.
• For the six months ended June 30, 2024, the company's revenue was $413.7 million, a 13% increase compared to $364.7 million in the same period last year.
• The net loss for the first six months of 2024 was $62.7 million, or $0.69 per share, compared to a net loss of $170.8 million, or $2.10 per share, in the prior year.
• The company's cash, cash equivalents, and marketable investment securities totaled $97.3 million as of June 30, 2024.
• Myriad Genetics has an asset-based revolving credit facility with a maximum principal commitment of $115 million, with $40 million outstanding and $41.5 million available as of June 30, 2024.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and improved net loss, but there are still challenges with profitability and some areas of decline. The strategic moves and new product launches are promising, but the company needs to continue to execute well to achieve long-term success.

Positives

• The company experienced a significant 15% year-over-year revenue growth in the second quarter of 2024.
• Prenatal and pharmacogenomics testing volumes showed strong growth, increasing by 12% and 10% respectively.
• The net loss improved significantly compared to the same period last year, decreasing from $116.1 million to $36.7 million for the quarter.
• The company launched the Foresight Universal Plus Test, expanding its product offerings.
• Myriad entered into a cross-licensing agreement with Personalis, Inc. for MRD detection technology, potentially enhancing future product development.
• GeneSight was added to Blue Shield of California's medical policy, expanding coverage for the test.
• The company achieved Great Place to Work Certification for 2024.

Negatives

• Tumor profiling test volumes decreased by 13% year-over-year.
• The company still reported a net loss of $36.7 million for the quarter and $62.7 million for the first six months of 2024.
• A $10.2 million impairment charge was recognized due to the sale of the EndoPredict business.
• Cash and cash equivalents decreased by $39.7 million from December 31, 2023 to June 30, 2024.

Risks

• The company faces risks related to changes in governmental or private insurers' coverage and reimbursement levels for its tests.
• Increased competition and the development of new competing tests pose a risk to the company's market share.
• The company may not be able to develop or achieve commercial success for additional tests in a timely manner.
• There are risks associated with delays or other problems with operating laboratory testing facilities.
• The company is subject to regulatory requirements and enforcement in the United States and foreign countries.
• The company may not be able to secure additional financing to fund its business if needed.
• There are risks related to security breaches, loss of data, and other disruptions, including from cyberattacks.
• The company may be unable to comply with financial or operating covenants under its credit or lending agreements.
• The company is subject to current and future investigations, claims, or lawsuits.

Future Outlook

The company plans to launch new products, such as FirstGene, Precise Liquid, and Precise minimal residual disease, which are expected to help accelerate growth. Myriad intends to develop and enhance its products and services to support growth, improve patient and provider experience, and reach more patients of all backgrounds. The company believes its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.

Management Comments

• The pillars of our long-term growth strategy are founded on investments in science and innovation, technology-enabled operations, an elevated customer experience, strong commercial execution, and scalable operations.
• We believe our path to continued growth is driven by articulating our clinical differentiation, raising awareness with patients who we believe would benefit from our testing products, and innovation that improves clinical outcomes, ease of use, and access.
• By investing in technology-enabled commercial tools, new laboratory facilities, advanced automation, and standardized processes and technology, we believe we will be able to reduce complexity and cost while enhancing our ability to scale and grow.

Industry Context

The announcement reflects a broader trend in the genetic testing and precision medicine industry, where companies are focusing on expanding their product portfolios and improving operational efficiency. The growth in prenatal and pharmacogenomics testing aligns with increasing demand for personalized healthcare solutions. The cross-licensing agreement for MRD detection technology indicates a strategic move towards advanced diagnostics, which is a key area of growth in the industry. The addition of GeneSight to Blue Shield of California's medical policy highlights the increasing acceptance and coverage of pharmacogenomic testing by major payers.

Comparison to Industry Standards

• Myriad's 15% revenue growth in Q2 2024 is a strong performance compared to some of its peers in the genetic testing industry, although specific comparisons are difficult without detailed financial data from competitors for the same period.
• Companies like Exact Sciences, which focuses on cancer diagnostics, and Invitae, which offers a broad range of genetic tests, are key competitors. Exact Sciences reported a 19% revenue increase in their most recent quarter, while Invitae has been facing financial challenges and restructuring.
• The 9% growth in testing volumes for Myriad is a positive sign, but it is important to compare this to the volume growth of other companies in the same space. For example, companies like Natera, which focuses on prenatal testing, have seen significant volume growth in recent periods.
• Myriad's focus on improving operational efficiency and reducing costs is a common theme in the industry, as companies strive to achieve profitability and scale their operations. The company's investment in technology-enabled tools and new laboratory facilities is in line with this trend.
• The cross-licensing agreement with Personalis for MRD detection technology is a strategic move that could give Myriad a competitive edge in the cancer diagnostics market. Other companies, such as Guardant Health and Adaptive Biotechnologies, are also heavily invested in MRD testing.
• The addition of GeneSight to Blue Shield of California's medical policy is a significant win for Myriad, as it expands access to the test and increases its potential market. Other companies in the pharmacogenomics space, such as Genomind and OneOme, are also working to expand coverage for their tests.

Corporate Governance

Legal Proceedings

• The company is involved in various disputes, claims, and legal actions, including class actions and other litigation, arising in the ordinary course of business.
• The company has settled stockholder derivative actions, agreeing to adopt certain corporate governance reforms and pay attorneys' fees and expenses not to exceed $0.95 million.
• The company has received recoupment requests from third-party payors for alleged overpayments.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, strategic decisions, and any legal proceedings.
• Employees may be affected by changes in compensation, benefits, and the company's overall performance.
• Customers will benefit from new product launches and improvements in patient and provider experience.
• Suppliers may be impacted by changes in the company's supply chain and purchasing decisions.
• Creditors will be impacted by the company's financial performance and ability to meet its debt obligations.

Next Steps

• The company plans to launch new products, such as FirstGene, Precise Liquid, and Precise minimal residual disease.
• Myriad will continue to develop and enhance its products and services to support growth and improve patient and provider experience.
• The company will continue to focus on disciplined management of key initiatives to drive long-term growth and profitability.

Key Dates

Keywords

genetic testing, precision medicine, oncology, women's health, pharmacogenomics, prenatal testing, hereditary cancer, tumor profiling, GeneSight, Foresight, MyRisk, MRD, minimal residual disease